X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TG-1000 is a prodrug of TG-0527, a new molecular entity and a potent cap-dependent endonuclease inhibitor being investigated in adult and adolescent patients with uncomplicated acute influenza infection.
Lead Product(s): TG-1000
Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Joincare Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
Under the agreement, Y.S.P. will develop and commercialize TaiGen's new small molecule drug, TG-1000, a virus replication inhibitor, for infections, in Malaysia and Singapore.
Lead Product(s): TG-1000
Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Y.S.P. Industries M Sdn Bhd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 10, 2023
Details:
Joincare will develop and commercialize TG-1000, a novel pan-influenza antiviral by interrupting viral replication and transmission via a cap-snatching mechanism, revealing efficacy against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses, in china.
Lead Product(s): TG-1000
Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD
Deal Size: Undisclosed Upfront Cash: $2.9 million
Deal Type: Licensing Agreement March 22, 2023
Details:
Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn® in S. Korea and Burixafor worldwide.
Lead Product(s): Burixafor
Therapeutic Area: Immunology Product Name: TG-0054
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GPCR Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 09, 2020
Details:
TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.
Lead Product(s): TG-1000
Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.
Lead Product(s): TG-1000
Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
Under the terms of the agreement, Luminarie will be responsible for the development, registration and commercialization of Taigexyn® in the territory and assume all associated costs.
Lead Product(s): Nemonoxacin
Therapeutic Area: Infections and Infectious Diseases Product Name: Taigexyn
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Luminarie
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
